FED降息预测竟暗含危机?华尔街大佬:预示衰退即将到来
- 0001年1月1日
注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Affimed NV是一家临床阶段的生物制药公司,致力于发现和开发癌症免疫疗法。该公司开发免疫肿瘤领域的候选产品,代表一种旨在利用人体自身免疫系统对抗肿瘤细胞的癌症研究方法。其产品包括AFM13、AFM13+过继性NK细胞、AFM13+抗PD-1、AMF24、AMF26、AMF28和AMF32。该公司正在将患者纳入针对AFM13的CD30阳性复发/难治性外周T细胞淋巴瘤的定向研究,以及AFM24治疗晚期EGFR表达实体瘤的1/2a剂量递增/扩展研究。其临床前候选产品包括用于治疗多发性骨髓瘤的AMF26,以及用于治疗多个肿瘤靶标的AMF28和AMF32。此外,该公司与Genentech合作,开发和商业化可治疗多种癌症的候选产品。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Thomas O. Hecht | 70 | 2007 | Chairman of Supervisory Board |
Ulrich M. Grau | 72 | 2013 | Member of Supervisory Board |
Mathieu Simon | 65 | 2018 | Member of Supervisory Board |
Annalisa Mary Jenkins | 56 | 2020 | Member of Supervisory Board |
Anton Hagenbeek | - | - | Member of Scientific Advisory Board |
Miroslav S. Ravic | 73 | - | Member of Scientific Advisory Board |
Susanne Becker | - | - | Member of Scientific Advisory Board |
Franck Morschhauser | - | - | Member of Scientific Advisory Board |
Bernhard R. M. Ehmer | 67 | 2016 | Independent Member of Supervisory Board |
Owen A. O'Connor | - | 2015 | Member of Scientific Advisory Board |
Ulrike Köhl | - | - | Member of Scientific Advisory Board |
Max S. Topp | - | - | Member of Scientific Advisory Board |
Andreas Engert | - | - | Member of Scientific Advisory Board |
Christian Hucke | - | - | Member of Scientific Advisory Board |
Stephen M. Ansell | - | 2015 | Member of Scientific Advisory Board |
Andrew Evens | - | 2016 | Member of Scientific Advisory Board |
Uta Kemmerich-Keil | 56 | 2021 | Independent Supervisory Director |
Constanze Ulmer-Eilfort | 61 | 2023 | Member of Supervisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核